Germany's Comparative Effectiveness Debate Concludes; Dossier Refinement Begins
Executive Summary
After clearing the last political hurdle in December, the German government's ordinance on a methodology to assess the added benefit of medicines will now face an even more complex task: being usefully applied to new products.
You may also be interested in...
European Regulatory Round-Up: Patents, Pricing And Parabens
European Union
European Regulatory Round-Up: Patents, Pricing And Parabens
European Union
Shire CEO Angus Russell On The Value Proposition For Drugs
Since 2008, Shire PLC 's market cap has nearly doubled ($8.3 billion to $16 billion) and its employee count has grown from 1,600 to roughly 4,300. Analysts say the U.K. company is on track to deliver its revenue guidance of 15% compound annual growth rate (CAGR) through 2015 – far above the expected anemic performance of most pharmaceutical companies.